Pivotal Trial For GSK/Xenoport’s Sustained-Release Restless Legs Drug Supports Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the drug could reach $958 million in 2013, analyst predicts, including RLS and neuropathic pain indications.